image: The authors made the rituximab fluorescent (FITC) and demonstrated that it binds to kidney sections (above) and to podocytes in culture (below). This is a major paradigm shift, as rituximab was thought to bind only to B-lymphocytes, the cells making immunoglobulins. This image relates to a paper that appeared in the June 1, 2011, issue of Science Translational Medicine, published by AAAS. The paper, by Dr. Alessia Fornoni of the University of Miami Miller School of Medicine in Miami and colleagues, was titled, "Rituximab Targets Podocytes in Recurrent Focal Segmental Glomerulosclerosis." view more
Credit: Image © Science/AAAS